Compare Gilead Sciences, Inc. (GILD) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Gilead Sciences, Inc. trades at $133.53 (market cap $163.51B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.71. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| GILD | USIG | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $52.69 |
52-Week Low | $108.22 | $50.50 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
USIG trades at $50.705, up 0.17% with bearish technical signals from moving averages and a neutral RSI. Recent news highlights a 63.4% surge in short interest as of April 15, 2026, per Defense World, indicating heightened bearish sentiment. Dividend payouts remain consistent, with the latest at $0.20 paid on July 7, 2026.
The outlook is cautious due to weak technical momentum and rising short interest, though dividends provide income stability. Key risks include market volatility and investor skepticism, while opportunities lie in potential mean reversion if bearish pressures ease. Monitor institutional flows for sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
